Neoplastic progression in Barrett's esophagus is a multistep process in which the metaplastic columnar epithelium sequentially evolves through a metaplasia-dysplasiacarcinoma sequence. The expression and DNA copy number of key cell cycle regulatory genes in paired normal and Barrett's esophagus samples was evaluated. Protein levels were evaluated in 60 formalin-®xed, paran-embedded human tissues by immunohistochemistry. DNA copy number from 20 fresh tissue pairs was analysed by Southern blot analysis. All normal mucosal samples expressed the p27 kip1 protein, but did not display appreciable nuclear staining for p16 kip4 , p21 cip1 or cyclins D1 and E. Barrett's metaplastic specimens displayed increased expression levels of p16 kip4 (74%), p21 cip1 (89%) and cyclins D1 (43%) and E (37%). p27 protein was absent in three cases. There was a signi®cant correlation between the expression of p16 kip4 and cyclin E, and p21 cip1 and p27 kip4 with cyclin D1. DNA analysis did not reveal any ampli®cation or deletion of these genes. Acid suppression, however, was associated with signi®cantly lower expression levels of key cell cycle proteins. Increased expression of key cell cycle regulatory genes appears to occur early in the neoplastic progression associated with Barrett's esophagus. Treatment with proton pump inhibitors appears to alter this increased expression. Oncogene (2001) 20, 7987 ± 7991.
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Keywords: cell cycle; Barrett's esophagus; cyclins; cyclin-dependent kinase inhibitors; proton pump inhibitors Introduction Barrett's esophagus (BE) is a common condition in which part of the normal esophageal squamous epithelium is replaced by a metaplastic columnar epithelium as a result of chronic gastroesophageal re¯ux (Barrett, 1957; Spechler and Goyal, 1996) . This specialized intestinal metaplasia is found in up to 10% of patients with severe gastroesophageal re¯ux disease. Furthermore, many individuals with mild or moderate re¯ux symptoms alone will have BE, which is associated with a 30 ± 100-fold increased risk of development of adenocarcinoma of the esophagus (Spechler and Goyal, 1996) . The pool of patients requiring surveillance endoscopy and biopsy for BE may constitute as much as 1 ± 2% of the adult population in developed countries. Hence, the clinical problem of BE has important public health and medical-economic rami®cations.
The exact pathophysiologic basis of progression from BE-associated metaplasia to frank carcinoma is still incompletely understood. Barrett's-associated cancers do not arise de novo, but rather evolve from a multi-step process in which the metaplastic columnar epithelium sequentially develops through a dysplasiacarcinoma sequence (Skinner et al., 1983; Hameeteman et al., 1989; Reid, 1991) . As BE progresses to dysplasia and adenocarcinoma, increased and uncoordinated cell proliferation and decreased expression of dierentiation markers have been observed (Fitzgerald and Triada®lopoulos, 1998) . Molecular analyses of Barrett's epithelium may provide insight into the nature and signi®cance of genetic events occurring during the multi-step process of esophageal adenocarcinogenesis. Thus, identi®cation of these molecular genetic changes and cellular physiology would be of interest in the context of early detection, prevention and treatment strategies.
Uncontrolled cellular proliferation is one hallmark of cancer, and there is increasing evidence that tumor cells have acquired damage to genes that directly regulate their cell cycle (Pines, 1991; Hunter and Pines, 1994; Hall and Peters, 1996; Pardee, 1989; Sherr, 1994) . Genetic alterations aecting the G 1 phase of the cell cycle are so frequent in human cancers that abnormalities in this pathway may actually be necessary for tumor development. Like the tumor suppressor protein p53, other proteins may participate in G 1 checkpoint functions regulating homeostatic tissue renewal throughout life. During the G 1 phase, cells respond to extracellular signals by advancing toward S phase and cell division, withdrawing from the cycle into a resting state, or undergoing apoptosis (Pardee, 1989; Sherr, 1994) . Unlike transit through the S, G 2 , and M phases, G 1 progression normally relies on stimulation by mitogens and can be blocked by anti-proliferative cytokines. Cancer cells tend to lose these normal control mechanisms and remain actively in the cell cycle. Oncogenic processes often target speci®c regulators of G 1 phase progression (Hunter and Pines, 1994; Hall and Peters, 1996) .
To date, some of the earliest markers of tumor progression in Barrett's-associated neoplasia have been DNA content (ploidy) and mutant p53 protein (Gimenez et al., 1999) . Other changes previously described in Barrett's lesions include ampli®cation of the HER-2/neu, micro-satellite instability, Rb deletion, rare APC mutations, low expression of E-cadherin, high Src-speci®c activity, and increased expression of Bcl-2, cyclin D1, Fas ligand, TGF-alpha and PCNA (Sherr, 1994; Gimenez et al., 1999; Brien et al., 2000; Younes et al., 1999; Reid et al., 1993; Redd et al., 1994; Flejou et al., 1994; Bilir et al., 1994; Finkel et al., 1994; Kim et al., 1992; Arber et al., 1996a) .
Adenocarcinomas arising in BE were once relatively uncommon. However, during the 1970s and 1980s, in white males, these cancers increased in incidence by 74%, a rate exceeding that of any other cancer in Europe and the United States (Blot et al., 1991 (Blot et al., , 1993 Pera et al., 1993; Chow et al., 1995) . Adenocarcinomas now constitute more than 50% of all esophageal cancers in the developed world (Blot et al., 1991 (Blot et al., , 1993 Pera et al., 1993; Chow et al., 1995) .
Epidemiological evidence suggests that patients with BE have longer exposure times to gastric acid than do patients with esophagitis or normal controls. There is sucient data to support the importance of acid re¯ux in the appearance and length of BE (Chow et al., 1995) . Anti-re¯ux therapy, i.e., with acid-suppressive drugs, generally relieves symptoms and heals concomitant esophagitis and Barrett's ulcers, and may prevent stricture formation. However, the role of acid re¯ux in the malignant transformation of the Barrett's epithelium is still not clear, and it remains to be seen whether acid-suppressive therapy can prevent transformation to esophageal adenocarcinoma (Gore et al., 1993; Clark and Demeetser, 1995) .
An increasing number of clinical and experimental studies have suggested that normalization of intraesophageal pH is the desired goal in the long-term treatment of patients with BE. Partial regression of BE, with the appearance and/or enlargement of squamous islands within the Barrett's epithelium, has been observed after treatment with proton pump inhibitors (Sampliner, 1994) , anti-re¯ux surgery (Sagar et al., 1995) , endoscopic laser ablation techniques (Lightdale, 1995; Overholt and Panjehpour, 1996) , or thermal electrocoagulation (Sampliner et al., 1996) . In an ex vivo BE culture model, short pulses of acid exposure increased proliferation (Fitzgerald et al., 1996) . On the other hand patients with BE treated with even a high dose of PPI (80 mg qd of omeprazole) have demonstrated only a minor change in the length of Barrett's mucosa. It was suggested that up to 30% of these patients continue to have an abnormal acid exposure in the esophagus. These results suggest that acid-suppressive therapy needs to be powerful enough to completely eliminate any acid pulses in order to eectively inhibit inappropriate cell proliferation in BE epithelia in vivo.
The present study was undertaken in order to determine whether abnormalities in the expression of several key cell cycle control genes occur in BEassociated neoplastic progression. Protein levels and DNA copy number of the genes p16, p21, p27, cyclin D1 and cyclin E were measured in a series of paired normal mucosal and BE samples. The current study showed that acid suppression decreases the expression of certain key cell cycle regulatory proteins, supporting the hypothesis that continuous long-term acid suppression decreases proliferation in vivo in BE patients.
Results
Samples were evaluated from 60 patients, 32 men and 28 women with a respective mean age of 63+6 (+s.e.) and 61+7 (range 31 ± 84 years).
BE was diagnosed only if the specimen showed intestinal metaplasia, presenting as columnar mucosa with a villiform surface and intestinal-type crypt lined by mucus-secreting columnar cells and goblet cells. Low and high-grade dysplasia were seen in seven and two patients respectively.
All normal appearing mucosa expressed the p27 protein. None of them displayed appreciable nuclear staining for p16, p21 or cyclins D1 and E. Rarely, in about one cell per 20 crypts, was positive nuclear staining noted in a cell near the base of the crypt.
The abnormalities identi®ed in BE are summarized in Table 1 . A representative staining is shown in Figure  1 . The most common alteration involved an increase in the p21 cip1 protein, which was overexpressed in 88% of cases. Increased p16 protein was observed in 73% of the samples and in three cases the p27 kip1 protein was not detected. Increased expression of cyclin D1 and cyclin E proteins were seen in 47 and 43% of the lesions respectively.
Increased expression of p21 was signi®cantly higher in men (93%) than in women (76%) (P50.05). There was a signi®cant correlation between the expression of p16 and cyclin E, and cyclin D1 and p21 and p27. These ®ndings were observed in both dysplastic and Southern blot analysis (data not shown) did not reveal any ampli®cation (41.5) or deletion (50.7) of p16, p21, p27, cyclin D1 and cyclin E genes.
Percentage of cell cycle abnormalities in BE samples in relation to drug consumption is summarized in Figures 2 and 3 . Patients (n=22) consuming proton pump inhibitor (PPI) had signi®cantly less cell cycle abnormalities than patients taking H 2 blockers (n=18) or antacids (n=20). All patients on PPI retained p16 activity, and only in 25% of the subjects was cyclin E overexpressed as compared to 79 and 41% for patients on H 2 blockers, and 45% and 65% in antacid consumers respectively. These dierences were highly signi®cant. Patients on PPI less often displayed increased expression of cyclin D1 and down-regulation of p21 and p27. Patients receiving antacids had the highest percentage of cell cycle abnormalities and patients taking H 2 blockers were between.
Discussion
Maintenance of normal epithelial dierentiation and proliferation is an important goal in cancer chemoprevention. Ex vivo acid has a dynamic eect on cell proliferation/dierentiation in BE. Eective intraesophageal acid suppression favors dierentiation and decreases proliferation (Quato-Lascar et al., 1999) .
BE is associated with cell cycle abnormalities without a signi®cant change in the respective DNA level. We suggest that increased nuclear expression of the oncogenes cyclin D1 (47%) and cyclin E (43%), and reduced levels of the tumor suppressor gene p27 kip1 (5%) might predispose the esophageal epithelium to malignant transformation. The increased expression of the cell cycle inhibitors p16 kip4 and p21 cip1 in BE may be a defense mechanism induced by the tumorigenic process. These results con®rmed our previous observation regarding increased expression of cyclin D1 in 46% of 69 Americans with BE (Arbet et al., 1996a) , and 71% of patients with esophageal adenocarcinomas (Arber et al., 1999 ). It appears that there is no molecular epidemiological dierence between patients from dierent parts of the Western Hemisphere, namely Israel and the USA. Reid et al. (1993) have suggested that an early event in neoplastic progression, in BE, is the mobilization of cells from the G 0 phase to G 1 , loss of control of the G 1 /S transition, and accumulation in G 2 . It is suggested that cell cycle abnormalities, and in particular increased expression of cyclins D1 and E, are early events during the multi-step process of esophageal adenocarcinomas, since increased expression of this protein is found in an approximately similar percentage as in esophageal adenocarcinomas. Those changes might be responsible for initiating malignant cell transformation.
Acid exposure induces proliferation and inhibits apoptosis in BE and in esophageal adenocarcinoma Figures 2 and 3 . It is the ®rst report demonstrating that suppression of acid exposure down-regulates the expression of cyclins D1 and E, and further increases the levels of p16 kip4 and p21 cip1 . The molecular abnormalities were detected only on the protein level and not in DNA. This suggests that episodes of acid re¯ux might trigger proliferation and inhibit program cell death signaling pathways. Therefore, long-term therapy with PPI is desirable and can prevent or inhibit the malignant transformation in BE patients consuming PPI. The current studies suggest, for the ®rst time, that episodes of acid re¯ux might trigger proliferation and inhibit program cell death signaling pathways. Thus, long term therapy with PPI is desirable and can prevent or inhibit the malignant transformation of BE. It is suggested that all the attempts, so far, to prevent this malignant transformation failed because of insucient acid suppression.
Material and methods

Patients and samples
A total of 60 formalin-®xed, paran-embedded specimens of BE were obtained from the departments of pathology at Columbia University in NewYork and Tel Aviv Medical Center. In 20 of the samples, obtained in Tel Aviv, fresh biopsies from BE and normal adjacent mucosa were taken and snapped frozen in liquid nitrogen. Acid-lowering drugs were recorded on the day the biopsies were obtained. Patients were included in the study only if they had received, for at least 3 months, a standard regimen of acid inhibition (e.g. omeprazol 20 mg qd, lansoprazol 30 mg qd, ranitidine 300 mg qd or famotidin 40 mg qd). During 6 years of follow-up no adenocarcinoma developed in this group of patients.
Immunohistochemistry
All immunohistochemical analyses were performed with an avidin-biotin complex immunoperoxidase technique. Four mm tissue sections were mounted on poly-L-lysine coated slides. After deparanization in Americlear (Baxter, McGaw Park, IL, USA) and absolute ethanol, sections were hydrated through a series of graded alcohol, distilled water, and phosphate-buered saline (PBS), at pH 7.4. Slides were then immersed in 10 mM citrate buer (pH=6) and microwaved at 750 W for a total of 10 min. After blocking with goat serum for 20 min, the primary antibodies were applied and incubated overnight at 48C in a high-humidity chamber. These included mouse monoclonal anti-p16 ink4 (Pharmingen, San Diego, CA, USA), p21 waf1 (Santa Cruz Biotech, Santa Cruz, CA, USA), p27
Kip1 (Transduction Laboratories, Lexington, KY, USA), cyclin D1 (Immunotech, Inc., Freemont, CA, USA) and cyclin E (Santa Cruz Biotech, Santa Cruz, CA, USA). Subsequent steps utilized the Vectastain rabbit Elite ABC kit (Vector Laboratories, Burlingame, CA, USA) according to the manufacturer's instructions. Color development was accomplished with a 0.375 mg/dl solution of a 3,3'-diamino-benzidine tetrahydro chloride (Sigma Chemical Co., St. Louis, MO, USA) containing 0.003% hydrogen peroxide. Slides were counter-stained with hematoxylin and dehydrated, and cover slips were applied using Acrytol mounting medium (Surgipath Medical Industries, Richmond, IL, USA).
Although all the concentrations of primary antibodies gave good nuclear staining, the optimal concentration that gave a minimal background was 5 mg/ml for cyclin D1 and 2 mg/ml for p16 ink4 , p21 waf1 , p27 Kip1 and cyclin E. Positive controls were breast adenocarcinoma for cyclin D1 and gastric adenocarcinoma for p16 ink4 , p21 waf1 , p27 Kip1 and cyclin E. As a negative control a duplicate section of each tissue sample was immunostained, but in the absence of the primary antibody. The speci®city of the antibodies has been demonstrated (data not shown) by inhibition of immunohistochemical staining in positive controls by pre-incubating the antibody with 1 mg of immunizing peptides for 1 h at 48C, representing approximately 100-fold excess of peptide over antibody.
Interpretation of immunohistochemical staining
Staining for cyclin D1 was interpreted by one author (H Habishoosh) and for p16, p21, p27 and cyclin E by another author (W Yasui). Both individuals are experienced surgical pathologists. Nuclear staining was considered positive if the chromogen was clearly detected in at least 10% of the nuclei within a microscopic ®eld. Up to 5% of the nuclei at the base of the crypt were positive. This however represents less than 0.1% of the nuclei in an average microscopic ®eld. Positive and negative controls were included within each batch of slides. To con®rm reproducibility, 25% of the slides were randomly chosen and scored twice in the same batch, and all batches were coded and blindly scored at least twice. Duplicate slides gave similar results.
DNA preparation
In 20 of these cases two biopsies from BE mucosa and two biopsies, 5 cm proximal to the lesion, were taken from normal appearing mucosa and snapped frozen in liquid nitrogen. The lesions were stored at 7808C for further analysis. DNA was extracted from neoplastic and nonneoplastic biopsies as previously described (Arber et al., 1996b , Jiang et al., 1992 .
Southern blot analysis
Ten mg of genomic DNA was digested to completion with the restriction enzymes HindIII or EcoRI. The digested DNA was electrophoresed through a 1% agarose gel. The DNA was then transferred to Hybond-N hybridization membranes as previously described (Arber et al., 1996b , Jiang et al., 1992 . Fifty ng of p16 ink4 , p21 waf1 , p27 Kip1 , cyclin D1 and cyclin E cDNA were used as probes. They were labeled with [a-32 P]-dCTP using the multi-prime DNA labeling system (Amersham, Arlington Heights, IL, USA) to a speci®c activity of 3610 8 c.p.m/ml, and added to the hybridization reaction at 658C for 16 ± 18 h. Following hybridization, the ®lters were washed in 26SSC, 0.1% SDS, initially at room temperature for 20 min and subsequently for several additional washes at 658C for 20 min each. The ®lters were then autoradiographed with Kodak XAR-5 X-ray ®lm and Kodak`lightning plus' intensi®er screens for 1 ± 7 days at 7708C. The autoradiograms were analysed by densitometric scanning. Equivalent loading in Southern blots was con®rmed by the housekeeping gene actin, and by repeating all assays at least twice.
Statistical analysis
The proportions of samples expressing the dierent genes from dierent histological categories were computed and then compared across categories for selected factors (including gender, age, cigarette smoking, alcohol consumption, and presence of dysplasia). When comparing proportions positive for staining across histological categories, Fisher and Chisquared tests were employed (Brier, 1980 ). McNemar's test (McNemar, 1994) was also conducted for testing asymmetry in the association between the dierent genetic markers.
